½ÃÀ庸°í¼­
»óǰÄÚµå
1571399

À¯·´ÀÇ °ñ°üÀý ħÀ±¿ë °üÀý³» ÁÖ»ç ½ÃÀå ±Ô¸ð ¹× ¿¹Ãø, Áö¿ªº° Á¡À¯À², µ¿Çâ, ¼ºÀå ±âȸ ºÐ¼® : À¯Çüº°, ÃÖÁ¾»ç¿ëÀÚº°, ±¹°¡º°

Europe Intra-Articular Injection for Osteoarticular Infiltrations Market Size and Forecast (2021 - 2031), Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Type, End User (Hospitals, Orthopedic Clinics, and Others), and Country

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: The Insight Partners | ÆäÀÌÁö Á¤º¸: ¿µ¹® 92 Pages | ¹è¼Û¾È³» : Áï½Ã¹è¼Û

    
    
    



¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

À¯·´ÀÇ °ñ°üÀý ħÀ±¿ë °üÀý³» ÁÖ»ç ½ÃÀå ±Ô¸ð´Â 2023³â 9,743¸¸ ´Þ·¯¿¡¼­ 2031³â 1¾ï 5,708¸¸ ´Þ·¯·Î 2023³âºÎÅÍ 2031³â±îÁö 6.2%ÀÇ CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

°ñ°üÀý¿° °üÀý³» ÁÖ»ç´Â °ñ°üÀý¿°¿¡ °É¸° °üÀý¿¡ Á÷Á¢ ¾à¹°À» ÁÖÀÔÇÏ´Â ÀÇ·á ½Ã¼úÀÔ´Ï´Ù. ÀÌ Á¢±Ù¹ýÀº ÅëÁõÀ» ¿ÏÈ­ÇÏ°í °üÀý ±â´ÉÀ» °³¼±ÇÏ´Â °ÍÀ» ¸ñÇ¥·Î ÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ÁÖ»çÀÇ ÀÌÁ¡¿¡ ´ëÇÑ ÀÇ·áÁø°ú ȯÀÚÀÇ ÀνÄÀÌ ³ô¾ÆÁö°í ÀÇ·á ÀÎÇÁ¶ó ¹× ±â¼ú Çõ½Å¿¡ ´ëÇÑ ÅõÀÚ°¡ Áõ°¡ÇÔ¿¡ µû¶ó ÀÌ·¯ÇÑ Ä¡·á¹ý¿¡ ´ëÇÑ Á¢±Ù¼ºÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. °ñ°üÀý¿°ÀÇ À¯º´·ü Áõ°¡¿Í ÁÖ»ç ±â¼úÀÇ ¹ßÀüÀº À¯·´ÀÇ °ñ°üÀý ħÀ±¿ë °üÀý³» ÁÖ»ç ½ÃÀå ±Ô¸ð È®´ë¿¡ ±â¿©ÇÏ´Â ÁÖ¸ñÇÒ ¸¸ÇÑ ¿äÀÎÀ¸·Î ²ÅÈü´Ï´Ù. ±×·¯³ª °üÀý³» ÁÖ»ç¿Í °ü·ÃµÈ ºÎÀÛ¿ëÀÌ À¯·´ÀÇ °ñ°üÀý ħÀ±¼º °üÀý³» ÁÖ»çÁ¦ ½ÃÀåÀÇ ¼ºÀåÀ» ÀúÇØÇϰí ÀÖ½À´Ï´Ù.

°üÀý³» ÁÖ»ç´Â °ñ°üÀý ħÀ±¿¡ ´ëÇÑ Çõ½ÅÀûÀÌ°í »õ·Î¿î Ä¡·á ºÐ¾ß Áß ÇϳªÀÔ´Ï´Ù. Á¦Á¶¾÷üµéÀº Çõ½ÅÀûÀÎ ¾à¹°ÀÇ ¾ÈÀü¼º, À¯È¿¼º ¹× ½Å·Ú¼ºÀ» º¸ÀåÇϱâ À§ÇØ ´Ù¾çÇÑ ÀÓ»ó½ÃÇèÀ» ÁøÇàÇϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, 2024³â 5¿ù ½º¿þµ§ÀÇ ½Ã³ªÆ®·Î´Â °ñ°üÀý¿° Ä¡·áÁ¦ Èĺ¸¹°Áú SYN321ÀÇ ÀÓ»ó½ÃÇèÀ» ÁøÇàÇϱâ À§ÇØ 373¸¸-736¸¸ ´Þ·¯ÀÇ ÁõÀÚ¸¦ ½ÃÀÛÇß½À´Ï´Ù. ÇöÀç 278¸¸ ´Þ·¯ÀÇ ¹Ì±¹ º¸Á¶±Ý ȹµæÀ» À§ÇÑ ¸¶Áö¸· ´Ü°è¿¡ ÀÖ½À´Ï´Ù. ¶ÇÇÑ, 2023³â 4¿ù¿¡´Â ½º¿þµ§ ½Ä¾àû°ú ½º¿þµ§ À±¸®À§¿øÈ¸·ÎºÎÅÍ SYN321ÀÇ 1/2a»ó ÀÓ»ó 1»ó ½ÃÇè ½ÂÀÎÀ» ¹Þ¾Æ 2023³â 4¿ù¿¡ ÀÓ»ó 1»ó ½ÃÇèÀ» °³½ÃÇÒ ¿¹Á¤ÀÔ´Ï´Ù. ÀÌ Áö¿ªÀÇ ´Ù¸¥ ½ÃÀå ±â¾÷µéµµ °üÀý³» ÁÖ»çÁ¦ ÀÓ»ó½ÃÇèÀ» ÁøÇàÇϰí ÀÖÀ¸¸ç, ÀÌ´Â Çõ½ÅÀûÀÎ Á¦Ç° °³¹ß·Î À̾îÁú ¼ö ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, 2022³â 8¿ù µ¶ÀÏÀÇ GrunenthalÀº ·¹Áö´ÏÆä¶óÅå½Å(RTX)ÀÇ ¼¼°è ÀÓ»ó 3»ó ÇÁ·Î±×·¥¿¡ ù ȯÀÚ¸¦ µî·ÏÇß½À´Ï´Ù. GrunenthalÀº À¯·´, ¹Ì±¹, ¶óƾ¾Æ¸Þ¸®Ä«, ³²¹Ì ¹× ÀϺ»ÀÇ ¾à 200°³ Áö¿ª¿¡¼­ 3°³ÀÇ ÀÓ»ó½ÃÇèÀ» ½Ç½ÃÇÏ¿© ¼ºÀο¡¼­ RTXÀÇ °üÀý³» ÁÖ»çÀÇ ¾ÈÀü¼º°ú È¿´ÉÀ» Á¶»çÇß½À´Ï´Ù. ÀÓ»ó¿¡¼­ °üÂûµÈ °á°ú´Â ÁÖ·Î ±âÁؼ±ºÎÅÍ 52ÁÖ±îÁö WOMAC(Western Ontario and McMaster Universities) °ñ°üÀý¿° Áö¼ö¿¡¼­ ½Åü ±â´É ¹× ÅëÁõ Á¡¼öÀÇ °³¼±¿¡ ÃÊÁ¡À» ¸ÂÃè½À´Ï´Ù. ÀÌ ÀÓ»ó 3»óÀÌ ¿Ï·áµÇ¸é RTX´Â À¯·´, ¹Ì±¹, ÀϺ»¿¡¼­ ÆÇ¸Å ½ÂÀÎÀ» ¹ÞÀ» ¿¹Á¤ÀÔ´Ï´Ù. ȸ»ç´Â 2024³â ½Å¾à Çã°¡ ½Åû¼­¸¦ Á¦ÃâÇÒ °èȹÀ̸ç, RTXÀÇ ½ÃÀå ÁøÀÔÀº 2025³âÀÌ µÉ ¼ö ÀÖÀ½À» ½Ã»çÇϰí ÀÖ½À´Ï´Ù. µû¶ó¼­ ½ÅÈï±¹ ½ÃÀå¿¡¼­ÀÇ ÀÓ»ó½ÃÇèÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ÀÌ Áö¿ªÀÇ Çõ½ÅÀûÀÎ Á¦Ç° °³¹ßÀÌ ÃËÁøµÇ¾î ÇâÈÄ ¸î ³â µ¿¾È À¯·´ÀÇ °ñ°üÀý ħÀ±¼º °üÀý³» ÁÖ»çÁ¦ ½ÃÀåÀÇ ¼ºÀå¿¡ ±â¿©ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

À¯Çüº° ÀλçÀÌÆ®

À¯Çüº°·Î À¯·´ÀÇ °ñ°üÀý ħÀ±¿ë °üÀý³» ÁÖ»ç ½ÃÀåÀº 1Çü Äݶó°Õ°ú È÷¾Ë·ç·Ð»êÀ¸·Î ±¸ºÐµË´Ï´Ù. È÷¾Ë·ç·Ð»ê ºÎ¹®Àº 2023³â À¯·´ÀÇ °ñ°üÀý ħÀ±¿ë °üÀý³» ÁÖ»ç ½ÃÀå¿¡¼­ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. È÷¾Ë·ç·Ð»ê ÁÖ»ç´Â ´Ù¸¥ Ä¡·á ¿É¼Ç¿¡ ¹ÝÀÀÇÏÁö ¾Ê´Â ȯÀÚÀÇ ¹«¸­ ÅëÁõÀ» Ä¡·áÇϱâ À§ÇØ Ã¤Åõǰí ÀÖ½À´Ï´Ù. ÃÖ±Ù È÷¾Ë·ç·Ð»ê ÁÖÀÔ ¿ä¹ýÀÇ ¹ßÀüÀ¸·Î ¼ºÀå ±Ëµµ°¡ Å©°Ô È®´ëµÇ°í ÀÖ½À´Ï´Ù. ½ÃÀå ³» ½ÅÁ¦Ç° °³¹ß ¹× µµÀÔ¿¡ ´ëÇÑ °­·ÂÇÑ ÁýÁßÀº ÀÌ ºÎ¹®ÀÇ ¼ºÀåÀ» µÞ¹ÞħÇÏ¿© ½ÃÀå ¼ºÀå¿¡ ±â¿©ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

The Centers for Disease Control and Prevention(¹Ì±¹ Áúº´ÅëÁ¦¿¹¹æ¼¾ÅÍ), World Health Organization(¼¼°èº¸°Ç±â±¸), National Center for Biotechnology Information(¹Ì±¹ »ý¸í°øÇÐÁ¤º¸¼¾ÅÍ) µîÀº À¯·´ÀÇ °ñ°üÀý ħÀ±¿ë °üÀý³» ÁÖ»ç ½ÃÀå º¸°í¼­¸¦ ÀÛ¼ºÇÒ ¶§ Âü°íÇÑ 1Â÷ ¹× 2Â÷ Á¤º¸ Áß ÀϺÎÀÔ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼Ò°³

Á¦2Àå ÁÖ¿ä ¿ä¾à

  • ÁÖ¿ä ÀλçÀÌÆ®

Á¦3Àå Á¶»ç ¹æ¹ý

  • 2Â÷ Á¶»ç
  • 1Â÷ Á¶»ç
    • °¡¼³ Ã¥Á¤
    • °Å½Ã°æÁ¦ ¿äÀÎ ºÐ¼®
    • ±âÃÊ ¼öÄ¡ ÀÛ¼º
    • µ¥ÀÌÅÍ »ï°¢Ãø·®
    • ±¹°¡ ·¹º§ µ¥ÀÌÅÍ

Á¦4Àå À¯·´ÀÇ °ñ°üÀý ħÀ±¿ë °üÀý³» ÁÖ»ç ½ÃÀå »óȲ

  • PEST ºÐ¼®
  • Äݶó°Õ Áֻ簡 HA Áֻ纸´Ù ¿ì¼öÇÑ ÀÌÀ¯¿¡ ´ëÇÑ Á¤º¸
  • °¡°Ý ºÐ¼®

Á¦5Àå À¯·´ÀÇ °ñ°üÀý ħÀ±¿ë °üÀý³» ÁÖ»ç ½ÃÀå : ÁÖ¿ä ½ÃÀå ¿ªÇÐ

  • °ñ°üÀý ħÀ±¿ë °üÀý³» ÁÖ»ç À¯·´ ½ÃÀå - ÁÖ¿ä ½ÃÀå ¿ªÇÐ
  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • °ñ°üÀý¿° À¯º´·ü »ó½Â
    • ÁÖ»ç ±â¼úÀÇ Áøº¸
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
    • °üÀý³» Áֻ翡 µû¸¥ ºÎÀÛ¿ë
  • ½ÃÀå ±âȸ
    • °ñ°üÀý¿°¿¡ ´ëÇÑ °üÀý³» ÁÖ»çÀÇ Àü·«Àû ´ëó
  • ÇâÈÄ µ¿Çâ
    • ÀÓ»ó½ÃÇè ¼ö Áõ°¡
  • ¼ºÀå ÃËÁø¿äÀΰú ¾ïÁ¦¿äÀÎÀÇ ¿µÇâ

Á¦6Àå À¯·´ÀÇ °ñ°üÀý ħÀ±¿ë °üÀý³» ÁÖ»ç ½ÃÀå ºÐ¼®

  • À¯·´ÀÇ °ñ°üÀý ħÀ±¿ë °üÀý³» ÁÖ»ç ½ÃÀå ¸ÅÃâ(2021-2031³â)
  • À¯·´ÀÇ °ñ°üÀý ħÀ±¿ë °üÀý³» ÁÖ»ç ½ÃÀå ¿¹Ãø¡¤ºÐ¼®

Á¦7Àå À¯·´ÀÇ °ñ°üÀý ħÀ±¿ë °üÀý³» ÁÖ»ç ½ÃÀå ºÐ¼® : À¯Çüº°

  • À¯Çü 1 Äݶó°Õ
  • È÷¾Ë·ç·Ð»ê

Á¦8Àå °ñ°üÀý ħÀ±¿ë °üÀý³» ÁÖ»ç ½ÃÀå ºÐ¼® : ÃÖÁ¾»ç¿ëÀÚº°

  • º´¿ø
  • Á¤Çü¿Ü°ú Ŭ¸®´Ð
  • ±âŸ

Á¦9Àå À¯·´ÀÇ °ñ°üÀý ħÀ±¿ë °üÀý³» ÁÖ»ç ½ÃÀå ºÐ¼® : ±¹°¡º°

  • À¯·´
    • µ¶ÀÏ
    • ¿µ±¹
    • ÇÁ¶û½º
    • ÀÌÅ»¸®¾Æ
    • ½ºÆäÀÎ
    • µ§¸¶Å©
    • ±âŸ À¯·´

Á¦10Àå ¾÷°è »óȲ

  • °ñ°üÀý ħÀ±¿ë °üÀý³» ÁÖ»ç ½ÃÀå ¼ºÀå Àü·«
  • À¯±âÀû ¼ºÀå Àü·«
  • ¹«±âÀû ¼ºÀå Àü·«
    • ½ÃÀå °³¿ä

Á¦11Àå ±â¾÷ °³¿ä

  • Bioventus Inc
  • SEIKAGAKU CORPORATION
  • Maxigen Biotech Inc.
  • ?stem Medical Inc.
  • Sanofi SA
  • Ferring Pharmaceuticals
  • Fidia Pharma USA Inc.
  • Biotech Healthcare Group
  • Bioteck S.p.A.
  • I+MED

Á¦12Àå ºÎ·Ï

ksm 24.10.31

The Europe intra-articular injection for osteoarticular infiltrations market size is expected to grow from US$ 97.43 million in 2023 to US$ 157.08 million by 2031; it is projected to register a CAGR of 6.2% during 2023-2031.

Intra-articular injections for osteoarthritis are a medical procedure where medication is injected directly into a joint affected by osteoarthritis. This approach is intended to reduce pain and improve joint function. Increasing awareness among healthcare professionals and patients regarding the benefits of these injections, combined with increasing investment in healthcare infrastructure and innovation, is facilitating increased access to these treatments. The increasing prevalence of osteoarthritis and advancements in injection techniques are noteworthy factors contributing to the expansion of the Europe intra-articular injection for osteoarticular infiltrations market size. However, the side effects associated with intra-articular injections hinder the Europe intra-articular injection for osteoarticular infiltrations market growth.

Intra-articular injections are among the innovative and emerging fields of treatment for osteoarticular infiltrations. Manufacturers are involved in various clinical trials to ensure the safety, efficacy, and reliability of innovative drugs. For instance, in May 2024, the Swedish Company, Synartro, initiated a capital raise of between US$ 3.73 and 7.36 million to conduct a clinical study of the osteoarthritis candidate SYN321. It is in the final phase to secure an EU grant of US$ 2.78 million. Additionally, in April 2023, the company received approval from the Swedish Medical Products Agency and the Swedish Ethical Review Authority to start the phase 1/2a first-in-human clinical study of the investigational drug candidate SYN321. Other market players in the regions are also conducting clinical trials for intra-articular injections, which can lead to the development of innovative products. For instance, in August 2022, Grunenthal, a German company enrolled the first patient in its global clinical Phase III program for resiniferatoxin (RTX). Grunenthal has conducted three trials in ~200 locations across Europe, the US, Latin America, South Africa, and Japan to investigate the safety and effectiveness of intra-articular injections of RTX in adults. The outcomes observed in the trials mainly focus on an improvement in the physical function and pain score in the Western Ontario and McMaster Universities (WOMAC) osteoarthritis index from baseline to 52 weeks. Upon completion, the Phase III program is intended to provide marketing approval for RTX in Europe, the US, and Japan. The company intends to submit a new drug application in 2024, indicating the potential market entry of RTX in 2025. Therefore, the increasing number of clinical trials are expected to enhance the development of innovative products in the region, which, in turn, will contribute to the Europe intra-articular injection for osteoarticular infiltrations market growth in coming years.

Type-Based Insights

Based on type, the Europe intra-articular injection for osteoarticular infiltrations market is segmented into Type 1 collagen and hyaluronic acid. The hyaluronic acid segment held the largest Europe intra-articular injection for osteoarticular infiltrations market share in 2023 Hyaluronic acid injections are employed to treat knee pain in patients who were not responsive to other treatment options. Recent advancements in hyaluronic acid injection therapy have significantly expanded growth trajectory. A robust focus on developing and introducing novel products in the market is expected to support the growth of the segment, thereby contributing to market growth.

The Centers for Disease Control and Prevention, World Health Organization, and National Center for Biotechnology Information are among the primary and secondary sources referred to while preparing the Europe intra-articular injection for osteoarticular infiltrations market report.

Table Of Contents

1. Introduction

  • 1.1 The Insight Partners Research Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights

3. Research Methodology

  • 3.1 Secondary Research
  • 3.2 Primary Research
    • 3.2.1 Hypothesis formulation:
    • 3.2.2 Macro-economic factor analysis:
    • 3.2.3 Developing base number:
    • 3.2.4 Data Triangulation:
    • 3.2.5 Country level data:

4. Europe Intra-Articular Injection For Osteoarticular Infiltrations Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis
  • 4.3 Information on why collagen injections are better than HA injections
  • 4.4 Pricing Analysis

5. Europe Intra-Articular Injection For Osteoarticular Infiltrations Market - Key Market Dynamics

  • 5.1 Europe Intra-Articular Injection For Osteoarticular Infiltrations Market - Key Market Dynamics
  • 5.2 Market Drivers
    • 5.2.1 Rising Prevalence of Osteoarthritis
    • 5.2.2 Advancements in Injection Techniques
  • 5.3 Market Restraints
    • 5.3.1 Side Effects Associated with Intra-Articular Injections
  • 5.4 Market Opportunities
    • 5.4.1 Strategic Initiatives in Intra-Articular Injection for Osteoarticular Infiltrations
  • 5.5 Future Trends
    • 5.5.1 Increasing Number of Clinical Trials
  • 5.6 Impact of Drivers and Restraints:

6. Europe Intra-Articular Injection For Osteoarticular Infiltrations Market Analysis

  • 6.1 Europe Intra-Articular Injection For Osteoarticular Infiltrations Market Revenue (US$ Million), 2021-2031
  • 6.2 Europe Intra-Articular Injection For Osteoarticular Infiltrations Market Forecast and Analysis

7. Europe Intra-Articular Injection For Osteoarticular Infiltrations Market Analysis - by Type

  • 7.1 Type 1 Collagen
    • 7.1.1 Overview
    • 7.1.2 Type 1 Collagen: Europe Intra-Articular Injection For Osteoarticular Infiltrations Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.2 Hyaluronic Acid
    • 7.2.1 Overview
    • 7.2.2 Hyaluronic Acid: Europe Intra-Articular Injection For Osteoarticular Infiltrations Market - Revenue and Forecast to 2031 (US$ Million)

8. Europe Intra-Articular Injection For Osteoarticular Infiltrations Market Analysis - by End User

  • 8.1 Hospitals
    • 8.1.1 Overview
    • 8.1.2 Hospitals: Europe Intra-Articular Injection For Osteoarticular Infiltrations Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.2 Orthopedic Clinics
    • 8.2.1 Overview
    • 8.2.2 Orthopedic Clinics: Europe Intra-Articular Injection For Osteoarticular Infiltrations Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.3 Others
    • 8.3.1 Overview
    • 8.3.2 Others: Europe Intra-Articular Injection For Osteoarticular Infiltrations Market - Revenue and Forecast to 2031 (US$ Million)

9. Europe Intra-Articular Injection For Osteoarticular Infiltrations Market - Country Analysis

  • 9.1 Europe
    • 9.1.1 Europe Intra-Articular Injection For Osteoarticular Infiltrations Market Breakdown by Countries
    • 9.1.2 Europe Intra-Articular Injection For Osteoarticular Infiltrations Market Revenue and Forecast and Analysis - by Country
      • 9.1.2.1 Europe Intra-Articular Injection For Osteoarticular Infiltrations Market Revenue and Forecast and Analysis - by Country
      • 9.1.2.2 Germany: Europe Intra-Articular Injection For Osteoarticular Infiltrations Market - Revenue and Forecast to 2031 (US$ Million)
        • 9.1.2.2.1 Germany: Europe Intra-Articular Injection For Osteoarticular Infiltrations Market Breakdown by Type
        • 9.1.2.2.2 Germany: Europe Intra-Articular Injection For Osteoarticular Infiltrations Market Breakdown by Type 1 Collagen
        • 9.1.2.2.3 Germany: Europe Intra-Articular Injection For Osteoarticular Infiltrations Market Breakdown by End User
      • 9.1.2.3 United Kingdom: Europe Intra-Articular Injection For Osteoarticular Infiltrations Market - Revenue and Forecast to 2031 (US$ Million)
        • 9.1.2.3.1 United Kingdom: Europe Intra-Articular Injection For Osteoarticular Infiltrations Market Breakdown by Type
        • 9.1.2.3.2 United Kingdom: Europe Intra-Articular Injection For Osteoarticular Infiltrations Market Breakdown by Type 1 Collagen
        • 9.1.2.3.3 United Kingdom: Europe Intra-Articular Injection For Osteoarticular Infiltrations Market Breakdown by End User
      • 9.1.2.4 France: Europe Intra-Articular Injection For Osteoarticular Infiltrations Market - Revenue and Forecast to 2031 (US$ Million)
        • 9.1.2.4.1 France: Europe Intra-Articular Injection For Osteoarticular Infiltrations Market Breakdown by Type
        • 9.1.2.4.2 France: Europe Intra-Articular Injection For Osteoarticular Infiltrations Market Breakdown by Type 1 Collagen
        • 9.1.2.4.3 France: Europe Intra-Articular Injection For Osteoarticular Infiltrations Market Breakdown by End User
      • 9.1.2.5 Italy: Europe Intra-Articular Injection For Osteoarticular Infiltrations Market - Revenue and Forecast to 2031 (US$ Million)
        • 9.1.2.5.1 Italy: Europe Intra-Articular Injection For Osteoarticular Infiltrations Market Breakdown by Type
        • 9.1.2.5.2 Italy: Europe Intra-Articular Injection For Osteoarticular Infiltrations Market Breakdown by Type 1 Collagen
        • 9.1.2.5.3 Italy: Europe Intra-Articular Injection For Osteoarticular Infiltrations Market Breakdown by End User
      • 9.1.2.6 Spain: Europe Intra-Articular Injection For Osteoarticular Infiltrations Market - Revenue and Forecast to 2031 (US$ Million)
        • 9.1.2.6.1 Spain: Europe Intra-Articular Injection For Osteoarticular Infiltrations Market Breakdown by Type
        • 9.1.2.6.2 Spain: Europe Intra-Articular Injection For Osteoarticular Infiltrations Market Breakdown by Type 1 Collagen
        • 9.1.2.6.3 Spain: Europe Intra-Articular Injection For Osteoarticular Infiltrations Market Breakdown by End User
      • 9.1.2.7 Denmark: Europe Intra-Articular Injection For Osteoarticular Infiltrations Market - Revenue and Forecast to 2031 (US$ Million)
        • 9.1.2.7.1 Denmark: Europe Intra-Articular Injection For Osteoarticular Infiltrations Market Breakdown by Type
        • 9.1.2.7.2 Denmark: Europe Intra-Articular Injection For Osteoarticular Infiltrations Market Breakdown by Type 1 Collagen
        • 9.1.2.7.3 Denmark: Europe Intra-Articular Injection For Osteoarticular Infiltrations Market Breakdown by End User
      • 9.1.2.8 Rest of Europe: Europe Intra-Articular Injection For Osteoarticular Infiltrations Market - Revenue and Forecast to 2031 (US$ Million)
        • 9.1.2.8.1 Rest of Europe: Europe Intra-Articular Injection For Osteoarticular Infiltrations Market Breakdown by Type
        • 9.1.2.8.2 Rest of Europe: Europe Intra-Articular Injection For Osteoarticular Infiltrations Market Breakdown by Type 1 Collagen
        • 9.1.2.8.3 Rest of Europe: Europe Intra-Articular Injection For Osteoarticular Infiltrations Market Breakdown by End User

10. Industry Landscape

  • 10.1 Overview
  • 10.2 Growth Strategies in Intra-Articular Injection For Osteoarticular Infiltrations Market
  • 10.3 Organic Growth Strategies
    • 10.3.1 Overview
  • 10.4 Inorganic Growth Strategies
    • 10.4.1 Overview

11. Company Profiles

  • 11.1 Bioventus Inc
    • 11.1.1 Key Facts
    • 11.1.2 Business Description
    • 11.1.3 Products and Services
    • 11.1.4 Financial Overview
    • 11.1.5 SWOT Analysis
    • 11.1.6 Key Developments
  • 11.2 SEIKAGAKU CORPORATION
    • 11.2.1 Key Facts
    • 11.2.2 Business Description
    • 11.2.3 Products and Services
    • 11.2.4 Financial Overview
    • 11.2.5 SWOT Analysis
    • 11.2.6 Key Developments
  • 11.3 Maxigen Biotech Inc.
    • 11.3.1 Key Facts
    • 11.3.2 Business Description
    • 11.3.3 Products and Services
    • 11.3.4 Financial Overview
    • 11.3.5 SWOT Analysis
    • 11.3.6 Key Developments
  • 11.4 ?stem Medical Inc.
    • 11.4.1 Key Facts
    • 11.4.2 Business Description
    • 11.4.3 Products and Services
    • 11.4.4 Financial Overview
    • 11.4.5 SWOT Analysis
    • 11.4.6 Key Developments
  • 11.5 Sanofi SA
    • 11.5.1 Key Facts
    • 11.5.2 Business Description
    • 11.5.3 Products and Services
    • 11.5.4 Financial Overview
    • 11.5.5 SWOT Analysis
    • 11.5.6 Key Developments
  • 11.6 Ferring Pharmaceuticals
    • 11.6.1 Key Facts
    • 11.6.2 Business Description
    • 11.6.3 Products and Services
    • 11.6.4 Financial Overview
    • 11.6.5 SWOT Analysis
    • 11.6.6 Key Developments
  • 11.7 Fidia Pharma USA Inc.
    • 11.7.1 Key Facts
    • 11.7.2 Business Description
    • 11.7.3 Products and Services
    • 11.7.4 Financial Overview
    • 11.7.5 SWOT Analysis
    • 11.7.6 Key Developments
  • 11.8 Biotech Healthcare Group
    • 11.8.1 Key Facts
    • 11.8.2 Business Description
    • 11.8.3 Products and Services
    • 11.8.4 Financial Overview
    • 11.8.5 SWOT Analysis
    • 11.8.6 Key Developments
  • 11.9 Bioteck S.p.A.
    • 11.9.1 Key Facts
    • 11.9.2 Business Description
    • 11.9.3 Products and Services
    • 11.9.4 Financial Overview
    • 11.9.5 SWOT Analysis
    • 11.9.6 Key Developments
  • 11.10 I+MED
    • 11.10.1 Key Facts
    • 11.10.2 Business Description
    • 11.10.3 Products and Services
    • 11.10.4 Financial Overview
    • 11.10.5 SWOT Analysis
    • 11.10.6 Key Developments

12. Appendix

  • 12.1 About The Insight Partners
  • 12.2 Glossary of Terms
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦